Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
138.7 USD +3.65% Intraday chart for Illumina, Inc. +4.12% -0.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US Equity Markets Close Higher Thursday, Extending Gains From Wednesday MT
Illumina Shares Up After EU Court Adviser Says Antitrust Regulators Overstepped in Halting Grail Merger MT
Boost for Illumina as court adviser rejects EU merger powers RE
EU court should back Illumina's appeal against EU review of Grail deal, court adviser says RE
OTR Global Downgrades Illumina to Mixed From Positive MT
Illumina Investor Carl Icahn Withdraws Bid for Board Seat, Continues Legal Battle Over Grail Acquisition MT
Exclusive-Icahn drops Illumina board challenge threat, sources say RE
Illumina Insider Bought Shares Worth $991,672, According to a Recent SEC Filing MT
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on February 11, 2020. CI
Illumina, already facing pressure from Icahn, saw other activists at year end RE
UBS Adjusts Illumina Price Target to $145 From $111, Maintains Neutral Rating MT
TD Cowen Adjusts Price Target on Illumina to $150 From $144, Maintains Market Perform Rating MT
This time it's for real Our Logo
Barclays Adjusts Price Target on Illumina to $85 From $80, Maintains Underweight Rating MT
Citigroup Adjusts Price Target on Illumina to $145 From $120, Maintains Neutral Rating MT
Stifel Adjusts Price Target on Illumina to $160 From $125, Maintains Buy Rating MT
Baird Adjusts Price Target on Illumina to $146 From $144, Maintains Neutral Rating MT
Global markets live: Tesco, Boeing, Roche, Exxon Mobil, PepsiCo... Our Logo
ANALYST RECOMMENDATIONS : Lululemon, Nvidia, PayPal, Spotify, Uber... Our Logo
Illumina forecasts flat 2024 sales as sluggish demand drags on RE
Transcript : Illumina, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Illumina's Q4 Non-GAAP Earnings Unchanged, Revenue Rises MT
Illumina, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Illumina, Inc. Announces Goodwill Impairment for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (ILMN) ILLUMINA Posts Q4 EPS $0.14 vs. Street Est of $0.01 MT
Chart Illumina, Inc.
More charts
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
138.7 USD
Average target price
160 USD
Spread / Average Target
+15.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Illumina, Inc. - Nasdaq
  4. News Illumina, Inc.
  5. UBS Adjusts Illumina Price Target to $255 From $245, Maintains Neutral Rating